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A B S T R A C T
The expression of adhesion molecules Intercellular adhesion molecule-1(ICAM-1) and Vascular cell adhesion mole-
cule-1 (VCAM-1) is increased in lesional and in non-lesional skin of psoriatic patients, and play role in pathogenesis of
the disease. PUVA and UVB therapy are important treatments of psoriasis vulgaris. It has been demonstrated that UVA
and UVB therapies reduce expression of these molecules. In this investigation, phototherapy was used to treat psoriatic
patients. The expression of these molecules was examined by immunohistochemical method in lesional and non-lesional
skin of 10 patients with psoriasis vulgaris before and after treatment. Results showed increased expression of ICAM-1
molecules in keratinocytes, in perivascular infiltrate – lymphocytes, and in endothelial cells. The expression of VCAM-1
molecules was also increased, although with less intensity then ICAM-1. After therapy, the expression of the adhesion
molecules decreased together with a marked improvement of the disease. In conclusion, study demonstrated that pho-
totherapy improves psoriasis vulgaris probably through mechanisms acting on the adhesions molecules. Adverse reac-
tions due to intense or long lasting UVA (PUVA) and UVB therapies are immunosuppression and damage of DNA which
can lead to development of non-melanocytic skin tumors like basal cell carcinoma and squamous cell carcinoma, as well
as melanoma.
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Introduction
Intercellular adhesion molecule-1 (ICAM-1) and Vas-
cular cell adhesion molecule-1 (VCAM-1) play an impor-
tant role in the pathogenesis of psoriasis vulgaris1–3. Ad-
hesion molecules belong to three families of proteins: the
immunoglobulin superfamily, selectin and integrin fam-
ily. ICAM-1 on endothelial cells is connected to Lympho-
cyte Functional Associated Antigen-1 (LFA-1) as its li-
gand on lymphocytes which is important for the influx of
lymphocytes in perivascular infiltrate and for the prolif-
eration of keratinocytes.
Phototherapy with ultraviolet rays is a mainstay in
treatment of psoriasis. Today we use UVB or oral meto-
xsalen followed by UV-radiation (PUVA) therapies in
treatment of psoriasis vulgaris. Bath-PUVA and Re-PUVA,
i. e. a combination of PUVA therapy and oral retinoids
are also possible. Contraindications for PUVA therapy
are liver and kidney disease, cataract, systemic lupus
erythematosus, porphyries, malignant tumors, pregnan-
cy, xeroderma pigmentosum1. UVB or selective ultravio-
let radiation (SUP) is provided 3–4 times a week through
a period of 3–4 weeks. Narrow band UVB with frequency
of 311 nm is used which is less erythematogenic and less
carcinogenic then PUVA. Contraindications are photo-
dermatoses, lupus erythematosus, dysplastic naevus syn-
drome, xeroderma pigmentosum. The aim of this study
was to investigate the influence of PUVA or UVB radia-
tion on ICAM-1 and VCAM-1 adhesion molecules in pa-
tients suffering from psoriasis vulgaris.
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Materials and Methods
We examined 10 patients with psoriasis vulgaris. In
our investigation, we made comparison of the expression
of ICAM-1 and VCAM-1 adhesion molecules in lesional
and non-lesional skin of 10 psoriatic patients before and
after UV therapy. All of patients were observed and
treated at the Department of dermatovenereology. Study
was approved by the ethical commission of the Clinical
Hospital Centre, and all patients were given informal
consent. The diagnosis of psoriasis vulgaris was made on
clinical examination. After excisional biopsy, fresh frozen
sections of the skin underwent procedure as described
below. We used kit of labelled streptavidin biotin (LSAB)
reagents, DAKOLSAB+kit alkaline phosphatase univer-
sal K678 for immunochistochemical staining of ICAM-1
and VCAM-1 molecules. Cryostat sections were cut from
snap frozen tissue blocks and air dried for 2–24 hours.
Dried sections were ready for immediate processing, or
they were wrapped air-tight and stored frozen at –20 ºC
or lower. If stored frozen, sections should have been
brought to room temperature before unwrapping. Tissue
sections were fixed with acetone for 10 minutes. Alterna-
tively, fixation could have been performed after section-
ing and air drying, prior to frozen storage. Sections were
air-dried after fixation. Slides were submerged in buffer
bath for 5 minutes and then staining procedure started.
Staining procedure
Incubation lasted 60 minutes with primary antibody
or negative control reagents. The specimens were gently
rinsed with wash solution from a wash bottle and placed
in fresh butter bath. Excess buffer was immediately
tapped of and slides were wiped as before. Then yellow
drops from Bottle 2 were applied in sufficient amount to
cover specimen and incubated for 30 minutes. Slides
were wiped as before. Then red drops from Bottle 3
(Streptavidin) were applied in sufficient amount to cover
specimen, and incubated for 30 minutes. After that the
substrate-chromogen solution was prepared, and slides
were rinsed as before.
Substrate chromogen solution
Slides were wiped as before. After that substrate-
-chromogen solution was applied in sufficient amount to
cover specimen, and incubated for 10 minutes. Slides
were gently rinsed with distilled water from wash bottle.
Counter stain
Specimens were covered with hematoxylin. Alterna-
tively, slides were placed in a bath of hematoxylin, and
incubated for 2–5 minutes, depending on the strength of
the hematoxylin used, and gently rinsed with distilled
water from a wash bottle. Then they were dipped 10
times into wash bath filled with ammonia water, and
placed in distilled or deionized water for 2 minutes.
Mounting
Specimens were mounted and cover-slipped with an
aqueous-based mounting medium or a non-aqueous, per-
manent mounting medium. Recommendation was to use
a xylene substitute such as Histoclear for cleaning the
slides when preparing slides for permanent mounting
media. This procedure helped to eliminate the reduction
of staining of xylene. We interpreted the stain with
Olympus microscope and examined fuchsia-colored end-
-product at the site of the target antigen. We used simple
way of aritmetic median for statistic analysis, and aver-
age percentage of cell expressing adhesion receptors for
ICAM-1 and VCAM-1 molecules, in standard manner like
other authors 2,3,4,5, 6.
Results
General characteristics of patients are shown in Table
1. We detected ICAM-1 molecules on endothelial cells,
perivascular infiltrate and keratinocytes. VCAM-1 mole-
cules were also detected, but with less intensity espe-
cially in non-lesional skin. Our results are summarized
in Table 1. Positive immunohistochemical staining of
ICAM-1 and VCAM-1 molecules are shown in Table 1. We
excluded negative stain or +/– stain. Results showed
strong positivity of VCAM-1 and ICAM-1 molecules in
lesional skin in 10 cases (100%). In nonlesional skin,
ICAM-1 molecules were positive in 8 cases (80%), and
VCAM-1 molecules were positive in 6 cases (60%) of
psoriatic skin, before UV treatment. After UVB and
PUVA therapies, ICAM-1 molecules were positive in 8
cases (80%) and VCAM-1 molecules were positive in 9
cases (90%), in lesional skin.
Discussion and Conclusion
According to our results, ICAM-1 and VCAM-1 mole-
cules are highly expressed in lesional skin of patient with
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TABLE 1
EXPRESSION OF ADHESION MOLECULES ICAM-1 AND VCAM-1
IN LESIONAL AND NON-LESIONAL SKIN OF PSORIATIC
PATIENTS BEFORE AND AFTER UVB AND PUVA THERAPIES IN
ABSOLUTE NUMBERS AND PERCENTAGES
Topic Absolute value Percentage (%)
ICAM-1 lesional skin in
psoriatic patients
10 100
ICAM-1 non-lesional skin
in psoriatic patients
8 80
ICAM-1 lesional skin in
psoriatic patients after
UVB and Puva th.
8 80
VCAM-1 lesional skin in
psoriatic patients
10 100
VCAM-1 non-lesional skin
in psoriatic patients
6 60
VCAM-1 lesional skin after
UVB and PUVA th.
9 90
psoriasis vulgaris. ICAM-1 molecules are also expressed
in non-lesional skin, while VCAM-1 molecules are ex-
pressed with less intensity. We clearly demonstrated that
these adhesion molecules can play an important role in
the pathogenesis of psoriasis vulgaris. Some authors
found an increased serum concentration of soluble ICAM-1
(sICAM-1) molecules in patients with psoriasis vulgaris.
They correlated it with the severity of the disease (PASI
score)7,12,13, while others did not find an increased level of
sICAM-1 molecules after UVB and PUVA therapies8,9. It
was also demonstrated that sICAM-1 and sTNF-R1 mole-
cules were elevated in skin with psoriatic characteristics
in comparison to healthy skin11.
In our investigation we did not compare sICAM-1 lev-
els in patients, but only ICAM-1 molecule in the skin. It
is proven that ICAM-1and E-selectin molecules are hi-
ghly expressed on endothelial cells in lesional skin in pa-
tients with psoriasis10. VCAM-1 expression is weaker
then the expression of ICAM-1 in non-lesional skin. Re-
sults were similar in our investigation. IL-4 could be
up-regulated by UVB treatment and could selectively
stimulate VCAM-1 expression10. That is the reason why
there is higher expression of VCAM-1 molecules after
UVB treatment. UVB treatment decreased the adhesive
interaction between peripheral blood mononuclear cells
and endothelilal cells10. It has been demonstrated that
UVB radiation therapy reduces T cell infiltration and
disease severity (PASI score) in a period of few weeks. Af-
ter treatment of 6 MED with UVB, ICAM-1 staining was
reduced on endothelial cells in lesional skin in patients
with psoriasis10. PUVA tretament reduced the dermal in-
filtrate, but not ICAM-1 molecules that were expressed
on endothelial cells in examined patients. According to
our results, the expression of ICAM-1 and VCAM-1 di-
minished after UVB and PUVA therapies in lesional skin
of patients suffering from psoriasis vulgaris. The reason
for that was the influence of phototherapy on the immu-
nological process and on the adhesion molecules ICAM-1
and VCAM-1, which are important in progression and re-
gression of the disease. Other authors reported decrease
of ICAM-1 molecules in lesional skin of patients with pso-
riasis after 4 weeks of local therapy with calcitriol14. UVB
and PUVA therapies have many benefits for patients suf-
fering from psoriasis vulgaris, and are accepted well from
patients, but there are some side effects of this therapy
so careful examination is needed during the therapy.
Simple side effects include burning or erythema of the
skin after few exposures, but chronic actinic dermatitis
can also develop15. The most serious side effect is the de-
velopment of skin cancers after UVB and PUVA thera-
pies which include non-melanoma cancers like basall cell
carcinoma and squamous cell carcinoma in treated pa-
tients, as well as melanoma22,23,24,25. UVB therapy in-
creases the risk of non melanoma skin cancer in lower
percentage then PUVA16. PUVA increases the risk for de-
velopment of squamous cell carcinoma and basal cell car-
cinoma in lower percentage in psoriatic patients17. The
most severe side effect of PUVA therapy is the develop-
ment of malignant melanoma20.
In conclusion, we could confirm that PUVA and UVB
therapies are effective for patients suffering from psoria-
sis vulgaris. We followed the results of these therapies by
clinical appearance and by change in intensity of immuno-
histochemical staining of the adhesion molecules ICAM-1
and VCAM-1 in lesional skin and with slightly lower in-
tensity in nonlesional skin. This shows that they play an
important role in pathogenesis of psoriasis vulgaris. To-
day there is a targeted therapy like monoclonal antibod-
ies against LFA-1 (Efalizumab) which connects ICAM-1
molecules and has promising results in therapy of psoria-
sis vulgaris21. Careful monitoring of those patients is
necessary especially if therapy lasts for longer period of
time because it can lead to the development of non-
melanoma as well as melanoma skin cancers18,19. Our re-
sults were obtained on a small group of patients, so the
action of phototherapy on ICAM-1 and VCAM-1 mole-
cules needs further investigation.
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UTJECAJ UVA I UVB ZRA^ENJA NA ISPOLJAVANJE ICAM-1 I VCAM-1 MOLEKULA U
VULGARNOJ PSORIJAZI
S A @ E T A K
Ispoljavanje adhezijskih molekula ICAM-1 i VCAM-1 je povi{ena u promijenjenoj ko`i i nepromijenjenoj ko`i bole-
snika s psorijazom, te mogu imati ulogu etiopatogenezi psorijaze. UVA ili PUVA, te UVB se koriste kao terapija u
psorijazi. Poznato je da ta terapija smanjuje ispoljavanje molekula ICAM-1 i VCAM-1. U ovom istra`ivanju pokazali smo
utjecaj te terapije na na{oj Klinici za ko`ne i spolne bolesti, gdje smo istra`ivali ispoljavanje tih molekula imunohisto-
kemijskim bojenjem ko`e bolesnika prije terapije njihove promijenjene ko`e. Rezultati su pokazali poja~anu ekspresiju
ICAM-1 na keratinocitima, u perivaskularnom infiltratu-limfocitima i endotelnim stanicama, a isto se pokazalo za VCAM-1,
iako manjeg intenziteta. Poslije terapije smanjenje ispoljavanja obih molekula bilo je nazo~no u preparatima ko`e kao i
klini~ko pobolj{anje. U zaklju~ku mo`emo re}i da fototerapija (UVA i UVB) zrakama pobolj{ava psorijazu i mo`da u
tome ulogu igraju i adhezijske molekule. Ne`eljene reakcije fototerapije tijekom dugogodi{nje primjene UVA (PUVA) i
UVB su imunosupresija i o{te}enje DNA, koje mo`e dovesti do nastanka tumora poput bazalioma i spinalioma, te
melanoma.
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